Chairman of AM Biotech Went to The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) to Give A Special Lecture

The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) and the 8th Euro-Asian Association of Dermatovenereologists (EAAD) Congress were held on 8 Dec to10 Dec, 2024 at Kaohsiung, Taiwan.

This meeting, leading experts in skin diseases, a skin health, skin aesthetics,  from USA, Japan, Korea, Australia, Europe, and several other countries will share their knowledge of skin biology discuss its translational significance. Clinical lectures by experts within and outside of our communities will be delivered every day, high-quality symposiums will hold to review the latest advances in the management in skin related research, and a discussion of creative uses of artificial intelligence and telemedicine in dermatology will be initiated.

Dr. Ju-Sheng Shieh, chairman of Ascension Medical Biotechnology Co., Ltd (AM Biotech), was invited by the conference organizers to deliver a special lecture on the third day of the conference during the research forum titled “The latest not least about hair.” His presentation, titled “Discussing the efficiency and mechanism of bio-pulsed exosomes in beauty and hair growth from the perspective of miRNA and genes,” was addressed to over 500 dermatologists and skincare & Beauty research experts from both domestic and international backgrounds.

In his presentation, Dr. Shieh first introduced the differences between the self-developed bio-pulsed exosoms and conventional exosome (Naiev Exosome). He highlighted the technological advantages and features of the patented bio-pulsed technology platform. Finally, he introduced the successfully commercialized bio-pulsed exosomes specifically designed for skincare and hair growth, known as ExoGiov. The preliminary efficacy of ExoGiov was confirmed through NGS next-generation gene analysis, QPCR quantitative polymerase chain reaction, and cell viability tests, revealing several important characteristics:

  1. Derived from non-human source chicken embryonic mesenchymal stem cells from the laboratory with no specific disease source (SPF), and obtained international cosmetics certification (INCI), ensuring complete legality and compliance.
  2. Collaboration with the Tri-Service General Hospital,Taiwan for IRB human cell testing, with results co-published in the International Journal of Molecular Sciences.
  3. Efficacy reaching several times that of conventional exosomes, such as collagen and elastic protein proliferation rates exceeding 300%, fibroblast proliferation rates exceeding 50%, and follicle cell proliferation rates exceeding 120%. the all research findings and outstanding efficacy data have been published in “International Journal of Molecular Science”
  4. AM Bio uses panted extraction and lyophilization technology, achieving the purity of 99.99%, and whether in liquid or freeze-dried powder form, ExoGiov can be used and stored at room temperature.

Dr. Shieh concluded by stating that ExoGiov, in addition to having international cosmetics INCI, utilizes non-human source mesenchymal stem cells, making it a fully legal and compliant for cosmetics in the international market. He emphasized the unique induction and purification technology, making ExoGiov stand out with advantages such as high purity and room temperature storage. These qualities have attracted attention from international markets such as Europe, the United States, China, South Korea, and Japan. ExoGiov can be applied in the development of skincare and hair care products, positioning it as a noteworthy focus in the new generation of cosmetic ingredient.

Read Moreread more

A Breakthrough in Osteoporosis Treatment! Harnessing Exosomes from Skeletal Muscles for Bone Healing

This groundbreaking study shines a light on the exosomes present in these muscle-secreted humoral factors.

According to the EUROPE DIRECT CONTACT CENTRE Consultation Response: ExoGiov Comes from SPF Eggs and Does Not Fall under the Categories Mentioned in ANNEX II/419

All cosmetics related to animal sources and derived ingredients will be labeled ANNEX II/419. However,

Stem Cell Exosomes with Specific miRNAs: A New Frontier in Treating Male Pattern Baldness

As the exploration of exosomes in clinical settings progresses, there's growing anticipation for their integration